← All sarcoma trials
Recruiting nowN/AAges 18 Years to 60 Years

Intrathecal Dexmedetomidine-Fentanyl Combination Versus Fentanyl Alone as Adjuvant to Bupivacaine in Spinal Anesthesia for Above Knee Amputation in Sarcomas of Lower Extremity

Sponsor: National Cancer Institute, Egypt · NCT07276867 on ClinicalTrials.gov ↗

Bring this to your care team →

Conditions studied

IntrathecalDexmedetomidineFentanylBupivacaineSpinal AnesthesiaAbove Knee AmputationSarcomasLower Extremity

What it tests

  • Fentanyl + Dexmedetomidinedrug
  • Fentanyldrug

Where it's running1 site

1 international site

  • National Cancer Institute

    Cairo, Egypt 11796

    Recruiting now
See the official eligibility language

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

* Age from 18 to 60 years.
* Both sexes.
* American Society of Anesthesiologists (ASA) physical status of II-III.
* Height between 150-185 cm.
* Body mass index between 18-35 kg/m².
* Scheduled for above-knee amputation due to lower limb sarcomas.

Exclusion Criteria:

* Allergy to any of the investigated drugs.
* History of heart block, arrhythmia, or ongoing therapy with beta- or calcium channel- blockers, or angiotensin-converting-enzyme inhibitors.
* Contraindications to spinal anesthesia.
* Pregnancy or lactation.
* Presence of psychiatric illness or chronic pain conditions.

Updated 2025-12-11 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.